1. Home
  2. ATCH vs GBIO Comparison

ATCH vs GBIO Comparison

Compare ATCH & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AtlasClear Holdings Inc.

ATCH

AtlasClear Holdings Inc.

HOLD

Current Price

$0.25

Market Cap

39.2M

Sector

N/A

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.70

Market Cap

36.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATCH
GBIO
Founded
2022
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.2M
36.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ATCH
GBIO
Price
$0.25
$5.70
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$8.88
AVG Volume (30 Days)
4.2M
65.6K
Earning Date
02-18-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$12,303,120.00
$15,270,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
80.78
N/A
52 Week Low
$0.14
$3.00
52 Week High
$15.27
$12.40

Technical Indicators

Market Signals
Indicator
ATCH
GBIO
Relative Strength Index (RSI) 34.35 60.89
Support Level $0.25 $5.40
Resistance Level $0.27 $5.69
Average True Range (ATR) 0.02 0.22
MACD -0.00 0.04
Stochastic Oscillator 0.89 87.72

Price Performance

Historical Comparison
ATCH
GBIO

About ATCH AtlasClear Holdings Inc.

AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: